A Phase I, Open Label, Multicenter Study to Assess the Safety, Tolerability and Pharmacology of AZD2281 in Combination With Liposomal Doxorubicin (Caelyx) in Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Olaparib (Primary) ; Doxorubicin liposomal
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 18 Sep 2017 Planned End Date changed from 30 Sep 2017 to 31 Dec 2017.
- 05 Sep 2017 Planned End Date changed from 31 Aug 2017 to 30 Sep 2017.
- 16 Mar 2017 Planned End Date changed from 1 Dec 2016 to 31 Aug 2017.